Profile
Jeffrey M.
Goldberg served as President, Chief Executive Officer & Director at Spyre Therapeutics, Inc. in 2022-2023 and at Immunitas Therapeutics, Inc. in 2019-2021.
He was also the Chief Operating Officer at Akcea Therapeutics, Inc. from 2015 to 2019.
Prior to that, he was the Vice President of Business Operations at Proteostasis Therapeutics, Inc. from 2012 to 2014.
He also worked as the Senior Director of Product Operating Management at Genzyme Corp.
and as the Associate Vice President & Head of Project at Sanofi, Inc. Mr. Goldberg received a graduate degree from the Massachusetts Institute of Technology, an undergraduate degree from Cornell University, and an MBA from the MIT Sloan School of Management.
Former positions of Jeffrey Goldberg
| Companies | Position | End |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Chief Executive Officer | 2023-05-15 |
Immunitas Therapeutics, Inc.
 Immunitas Therapeutics, Inc. BiotechnologyHealth Technology Immunitas Therapeutics, Inc. provides cancer therapeutics services. The company was founded by Lea Hachigian, Kai Wucherpfennig, K. Dane Wittrup and Mario Suv? and is headquartered in Cambridge, MA. | Chief Executive Officer | 2021-11-15 |
| AKCEA THERAPEUTICS, INC. | Chief Operating Officer | 2019-09-22 |
| PROTEOSTASIS THERAPEUTICS, INC. | Chief Operating Officer | 2013-12-31 |
Sanofi, Inc.
 Sanofi, Inc. Drugstore ChainsRetail Trade Part of Abbott Laboratories, Sanofi, Inc. is a private company based in New York, NY. | Corporate Officer/Principal | - |
Training of Jeffrey Goldberg
| Massachusetts Institute of Technology | Graduate Degree |
| Cornell University | Undergraduate Degree |
| MIT Sloan School of Management | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Sanofi, Inc.
Sanofi, Inc. Drugstore ChainsRetail Trade Part of Abbott Laboratories, Sanofi, Inc. is a private company based in New York, NY. | Retail Trade |
Proteostasis Therapeutics, Inc.
 Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
Immunitas Therapeutics, Inc.
Immunitas Therapeutics, Inc. BiotechnologyHealth Technology Immunitas Therapeutics, Inc. provides cancer therapeutics services. The company was founded by Lea Hachigian, Kai Wucherpfennig, K. Dane Wittrup and Mario Suv? and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Jeffrey Goldberg
